MedTrace Logo

Pharmacological Regulation of Fat Transport in Metabolic Syndrome

NCT00632840 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2008-03-11

No results posted yet for this study

Summary

The purpose of this study is to determine whether atorvastatin and fenofibrate are effective in the treatment of lipid disorders in obese, insulin resistant subjects.

Conditions

Interventions

DRUG

Atorvastatin and fenofibrate

atorvastatin (40mg/day) fenofibrate (200mg/day)

Sponsors & Collaborators

  • National Heart Foundation, Australia

    collaborator OTHER

  • The University of Western Australia

    lead OTHER

Principal Investigators

  • Dick C Chan, PhD · The University of Western Australia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
25 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-06-30
Primary Completion
2002-12-31
Completion
2007-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00632840 on ClinicalTrials.gov